Impact of imatinib plus best supportive care in imatinib- and sunitinib-exposed patients with refractory advanced gastrointestinal stromal tumor.

Abstract

10064 Background: This retrospective non-randomized study investigated the effect on survival of imatinib (IM) plus best supportive care (BSC) after IM and sunitinib (SU) treatment for pts with locally advanced or metastatic gastrointestinal stromal tumor. Methods: 39 pts who had previously been exposed to both IM and SU and who were refractory to or intolerant of their latest therapy regimen were enrolled in this retrospective study. 13 pts were excluded due to participating in clinical trials. 26 pts were included in this study. Treatment regimen was BSC either with or without IM (400mg/day or less) according to pts selection. The primary endpoint was survival, and secondary endpoints were response rate assessed by CHOI and safety. Results: 14 pts were treated with IM and 12 were only BSC. Performance status (PS) at the termination of their latest therapy regimen was similar in both groups. Median dose of IM was 400 mg/day, and median duration of IM was 6 M. Median survival was greatly improved for IM pts although the overall difference in survival was marginally non-significant. (22M for IM and 4M for only BSC, p=0-059). Three pts (21%) were assessed as stable disease in IM group with no pts in the BSC group having a response of SD or better. IM was well tolerated, as in previous studies, and had little influence on PS. Conclusions: Treatment with IM may be associated with improvement in survival without deteriorating PS. Prospective study should be considered to confirm the efficacy of IM for pts with third-line or more treatment. No significant financial relationships to disclose.